Canadian Nanomedicine Expertise Database – NMIN – Nanomedicines Innovation Network

To facilitate collaboration and resource sharing within the Canadian nanomedicine research community, NMIN is pleased to provide this searchable database of nanomedicine-related expertise among established/independent Canadian professionals.

The database includes Canadian academic faculty at least at the assistant professor level, as well as other Canadian professionals in academia, industry, or regulatory agencies who have passed their probationary period. If you meet these criteria and wish to be included in the database, please provide us your information here.

The table below can be searched by any field.

All	Institution	Researcher	Nanodelivery type	Targeting approach	Application	Disease model	Protocols	Instrumentation	Auxilliary expertise
Researcher: Theresa M Allen Institution: University of Alberta / University of British Columbia (UBC) Nanodelivery type Lipid-based Polymer-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: mRNA/samRNA; ASO Peptide/protein delivery Disease model(s) Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Protocols: Safety/pharmacology	University of Alberta / University of British Columbia (UBC)	Theresa M Allen	Lipid-based Polymer-based	Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: mRNA/samRNA; ASO Peptide/protein delivery	Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)	Safety/pharmacology
Researcher: Ildiko Badea Institution: University of Saskatchewan Nanodelivery type Lipid-based Inorganic Targeting approach Physical targeting: pH sensitive Application Drug delivery Gene delivery: DNA, siRNA Peptide/protein delivery Disease model(s) Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model) Instrumentation: Synchrotron techniques Auxiliary expertise: Other: Human research ethics	University of Saskatchewan	Ildiko Badea	Lipid-based Inorganic	Physical targeting: pH sensitive	Drug delivery Gene delivery: DNA, siRNA Peptide/protein delivery	Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model)		Synchrotron techniques	Other: Human research ethics
Researcher: Marc A Gauthier Institution: Institut National de la Recherche Scientifique Nanodelivery type Polymer-based Targeting approach Active Targeting: Antibody or antibody fragments; Peptide; Aptamer Physical Targeting: pH sensitive; Temperature sensitive; Other (ROS; Enzymes; Thiol-Disulfide; etc.) Application Drug delivery: Soluble molecules Peptide/protein delivery Disease model(s) Cancer (In vitro, In vivo xenograft model, Primary cells) Other: several diseases (In vitro, In vivo) Auxiliary expertise: Non-nano delivery systems	Institut National de la Recherche Scientifique	Marc A Gauthier	Polymer-based	Active Targeting: Antibody or antibody fragments; Peptide; Aptamer Physical Targeting: pH sensitive; Temperature sensitive; Other (ROS; Enzymes; Thiol-Disulfide; etc.)	Drug delivery: Soluble molecules Peptide/protein delivery	Cancer (In vitro, In vivo xenograft model, Primary cells) Other: several diseases (In vitro, In vivo)			Non-nano delivery systems
Researcher: Ken Harder Institution: University of British Columbia (UBC) Nanodelivery type Lipid-based Targeting approach Other: 5 or 6 component LNPs for immune cell specific targeting Application Gene delivery: mRNA/samRNA Disease model(s) Cancer (In vitro, In vivo syngeneic model, In vivo metastatic model) Other: Alzheimer’s, obesity and atherosclerosis (In vitro, In vivo; mouse models) Protocols: Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting Instrumentation: CyTOF Auxiliary expertise: Non-nano delivery systems	University of British Columbia (UBC)	Ken Harder	Lipid-based	Other: 5 or 6 component LNPs for immune cell specific targeting	Gene delivery: mRNA/samRNA	Cancer (In vitro, In vivo syngeneic model, In vivo metastatic model) Other: Alzheimer’s, obesity and atherosclerosis (In vitro, In vivo; mouse models)	Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting	CyTOF	Non-nano delivery systems
Researcher: Umar Iqbal Institution: National Research Council of Canada Nanodelivery type Lipid-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide Physical targeting: Other (novel lipids and new lipid chemistry) Application Gene delivery: mRNA/samRNA; ASO Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model, Human) Rare diseases (Human) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics	National Research Council of Canada	Umar Iqbal	Lipid-based	Active targeting: Antibody or antibody fragments; Peptide Physical targeting: Other (novel lipids and new lipid chemistry)	Gene delivery: mRNA/samRNA; ASO	Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model, Human) Rare diseases (Human)	Safety/pharmacology (Pre-GLP toxicity); Microfluidics
Researcher: Jessica Kalra Institution: University of British Columbia (UBC) Nanodelivery type Lipid-based Application Drug delivery: Soluble molecules; Insoluble molecules Disease model(s) Cancer (In vitro, Organoid) Other: Neurological and inflammatory disease (In vitro, Organoid) Protocols: Microfluidics Auxiliary expertise: Other: In vivo modelling and imaging	University of British Columbia (UBC)	Jessica Kalra	Lipid-based		Drug delivery: Soluble molecules; Insoluble molecules	Cancer (In vitro, Organoid) Other: Neurological and inflammatory disease (In vitro, Organoid)	Microfluidics		Other: In vivo modelling and imaging
Researcher: Sherry Leung Institution: Precision NanoSystems Nanodelivery type Lipid-based Targeting approach Gene delivery Protocols: Microfluidics	Precision NanoSystems	Sherry Leung	Lipid-based		Gene therapy		Microfluidics
Researcher: Shyh-Dar Li Institution: University of British Columbia (UBC) Nanodelivery type Lipid-based Polymer-based Targeting approach Other: EPR effect, protein corona Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery Disease model(s) Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Rare diseases (In vivo: cancer, genetic diseases) Diabetes (In vivo: STZ induced) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics	University of British Columbia (UBC)	Shyh-Dar Li	Lipid-based Polymer-based	Other: EPR effect, protein corona	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery	Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Rare diseases (In vivo: cancer, genetic diseases) Diabetes (In vivo: STZ induced)	Safety/pharmacology (Pre-GLP toxicity) Microfluidics
Researcher: Michel Meunier Institution: Polytechnique Montreal Nanodelivery type Lipid-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments Physical targeting: Light sensitive Application Drug delivery: Soluble molecules Gene delivery: siRNA, mRNA/samRNA Disease model(s) Cancer (In vitro) Other: ophthalmology (In vitro)	Polytechnique Montreal	Michel Meunier	Lipid-based Inorganic	Active targeting: Antibody or antibody fragments Physical targeting: Light sensitive	Drug delivery: Soluble molecules Gene delivery: siRNA, mRNA/samRNA	Cancer (In vitro) Other: ophthalmology (In vitro)
Researcher: Raymond Reilly Institution: University of Toronto Nanodelivery type Inorganic Targeting approach Other: Local intratumoural infusion or implantation of gold nanoparticles Application Other: Radioisotope delivery Disease model(s) Cancer (In vitro) Protocols: Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing Instrumentation: Radioisotope measurement and small animal imaging systems (SPECT and PET) Auxiliary expertise: Regulatory science	University of Toronto	Raymond Reilly	Inorganic	Other: Local intratumoural infusion or implantation of gold nanoparticles	Other: Radioisotope delivery	Cancer (In vitro)	Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing	Radioisotope measurement and small animal imaging systems (SPECT and PET)	Regulatory science
Researcher: Manish Sadarangani Institution: University of British Columbia (UBC) Nanodelivery type Other: bacterial outer membrane vesicles Targeting approach Active targeting: Antibody or antibody fragments Application Other: vaccine delivery Disease model(s) Infectious diseases (Bacterial infections; In vitro [cells], In vivo [rodent]; BioSafety Level 2) Auxiliary expertise: Regulatory science	University of British Columbia (UBC)	Manish Sadarangani	Other: bacterial outer membrane vesicles	Active targeting: Antibody or antibody fragments	Other: vaccine delivery	Infectious diseases (Bacterial infections; In vitro [cells], In vivo [rodent]; BioSafety Level 2)			Regulatory science
Researcher: Gilbert Walker Institution: University of Toronto Nanodelivery type Lipid-based Polymer-based Targeting approach Active targeting: Antibody or antibody fragments; Small molecule Physical targeting: pH sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: siRNA, ASO Nano-imaging: Diagnostics Disease model(s) Cancer (In vitro) Infectious diseases (Viral infections; Bacterial infections; BioSafety Level 2; In vitro [cells], In vivo [rodent]) Protocols: Microfluidics Instrumentation: high resolution mechanical and IR imaging	University of Toronto	Gilbert Walker	Lipid-based Polymer-based	Active targeting: Antibody or antibody fragments; Small molecule Physical targeting: pH sensitive	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: siRNA, ASO Nano-imaging: Diagnostics	Cancer (In vitro) Infectious diseases (Viral infections; Bacterial infections; BioSafety Level 2; In vitro [cells], In vivo [rodent])	Microfluidics	high resolution mechanical and IR imaging
Researcher: Xiao Yu (Shirley) Wu Institution: University of Toronto Nanodelivery type Polymer-based Other: Polymer-lipid hybrid, polymer-lipid-inorganic based Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive; Other (oxidative stress, disease state biomarkers) Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; Other (MRI) Disease model(s) Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Diabetes (In vitro, In vivo: diabetic rats/mice) Other: neurodegenerative diseases (In vitro, Organoid, In vivo: Alzheimer’s mice, lung injury models) Protocols: Safety/pharmacology Auxiliary expertise: Non-nano delivery systems	University of Toronto	Xiao Yu (Shirley) Wu	Polymer-based Other: Polymer-lipid hybrid, polymer-lipid-inorganic based	Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive; Other (oxidative stress, disease state biomarkers)	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO< Peptide/protein delivery Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; Other (MRI)	Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Diabetes (In vitro, In vivo: diabetic rats/mice) Other: neurodegenerative diseases (In vitro, Organoid, In vivo: Alzheimer’s mice, lung injury models)	Safety/pharmacology		Non-nano delivery systems